$1.09
-0.03 (-2.68%)
Open$1.11
Previous Close$1.12
Day High$1.12
Day Low$1.05
52W High$4.19
52W Low$0.81
Volume—
Avg Volume175.4K
Market Cap12.43M
P/E Ratio—
EPS$-1.55
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,891.7% upside
Current
$1.09
$1.09
Target
$32.61
$32.61
$25.28
$32.61 avg
$46.79
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.43M | 2.52M | 2.31M |
| Net Income | 150.5K | 215.1K | 194.2K |
| Profit Margin | 6.2% | 8.5% | 8.4% |
| EBITDA | 295.2K | 302.7K | 296.9K |
| Free Cash Flow | 147.2K | 165.8K | 140.8K |
| Rev Growth | +21.7% | -7.9% | -0.3% |
| Debt/Equity | 0.76 | 0.80 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |